REFERENCES
1. Hu C. Grants supporting research in China. Eur Heart J 2018;39:2342-4.
2. Wang M, Cao R, Zhang L, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res 2020;30:269-71.
3. Grein J, Ohmagari N, Shin D, et al. Compassionate Use of Remdesivir for Patients with Severe Covid-19. N Engl J Med 2020;382:2327-36.
4. Kalil AC, Patterson TF, Mehta AK, et al. ACTT-2 Study Group Members. Baricitinib plus Remdesivir for Hospitalized Adults with Covid-19. N Engl J Med 2021;384:795-807.
5. RECOVERY Collaborative Group, Horby P, Lim WS, Emberson JR, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J Med 2021;384:693-704.
6. Riva L, Yuan S, Yin X, et al. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. Nature 2020;586:113-9.
7. Couzin-Frankel J. Antiviral pills could change pandemic’s course. Science 2021;374:799-800.
8. Ledford H. COVID antiviral pills: what scientists still want to know. Nature 2021;599:358-9.
9. Li R, Hou Y, Huang J, et al. Lianhuaqingwen exerts anti-viral and anti-inflammatory activity against novel coronavirus (SARS-CoV-2). Pharmacol Res 2020;156:104761.
10. Long QX, Liu BZ, Deng HJ, et al. Antibody Responses to SARS-CoV-2 in Patients With COVID-19. Nat Med 2020;26:845-8.
11. Chi X, Yan R, Zhang J, et al. A neutralizing human antibody binds to the N-terminal domain of the Spike protein of SARS-CoV-2. Science 2020;369:650-5.
12. Ortigoza MB, Yoon H, Goldfeld KS, et al. Efficacy and Safety of COVID-19 Convalescent Plasma in Hospitalized Patients: A Randomized Clinical Trial. JAMA Intern Med 2022;182:115-26.
13. Park H, Tarpey T, Liu M, et al. Development and Validation of a Treatment Benefit Index to Identify Hospitalized Patients With COVID-19 Who May Benefit From Convalescent Plasma. JAMA Netw Open 2022;5:e2147375.
14. Duan K, Liu B, Li C, et al. Effectiveness of convalescent plasma therapy in severe COVID-284 19 patients. Proc Natl Acad Sci U S A 2020;117:9490-6.
15. Grifoni A, Weiskopf D, Ramirez SI, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell 2020;181:1489-501.e15.
16. Chandrashekar A, Liu J, Martinot AJ, et al. SARS-CoV-2 infection protects against rechallenge in rhesus macaques. Science 2020;369:812-7.
17. Yu J, Tostanoski LH, Peter L, et al. DNA vaccine protection against SARS-CoV-2 in rhesus macaques. Science 2020;369:806-11.
18. Zhu FC, Li YH, Guan XH, et al. Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial. Lancet 2020;395:1845-54.
19. Zhu FC, Guan XH, Li YH, et al. COVID-19 vaccine in healthy adults aged 18 years or older: a randomized, double-blind, placebo-controlled, phase 2 trial. Lancet 2020;396:479-88.
20. Gao Q, Bao L, Mao H, et al. Development of an inactivated vaccine candidate for SARS-CoV-2. Science 2020;369:77-81.
21. Dai L, Zheng T, Xu K, et al. A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS. Cell 2020;182:722-33.e11.
22. Ma LY, Chen WW, Gao RL, et al. China cardiovascular diseases report 2018: an updated summary. J Geriatr Cardiol 2020;17:1-8.
23. Weckbach LT, Schweizer L, Kraechan A, et al. EMB Study Group. Association of Complement and MAPK Activation With SARS-CoV-2-Associated Myocardial Inflammation. JAMA Cardiol 2022;7:286-97.
24. Aschman T, Schneider J, Greuel S, et al. Association Between SARS-CoV-2 Infection and Immune-Mediated Myopathy in Patients Who Have Died. JAMA Neurol 2021;78:948-60.
25. Bois MC, Boire NA, Layman AJ, et al. COVID-19-Associated Nonocclusive Fibrin Microthrombi in the Heart. Circulation 2021;143:230-43.
26. Kawakami R, Sakamoto A, Kawai K, et al. Pathological Evidence for SARS-CoV-2 as a Cause of Myocarditis: JACC Review Topic of the Week. J Am Coll Cardiol 2021;77:314-25.
27. Talasaz AH, Sadeghipour P, Kakavand H, et al. Recent Randomized Trials of Antithrombotic Therapy for Patients With COVID-19: JACC State-of-the-Art Review. J Am Coll Cardiol 2021;77:1903-21.
28. Gorecka M, Thirunavukarasu S, Levelt E, Greenwood JP. Multiple Etiologies to Myocardial Injury in COVID-19. JACC Case Rep 2021;3:971-2.
29. Shaw KE, Cavalcante JL, Han BK, Gössl M. Possible Association Between COVID-19 Vaccine and Myocarditis: Clinical and CMR Findings. JACC Cardiovasc Imaging 2021;14:1856-61.
30. Kim HW, Jenista ER, Wendell DC, Azevedo CF, Campbell MJ, Darty SN, Parker MA, Kim RJ. Patients With Acute Myocarditis Following mRNA COVID-19 Vaccination. JAMA Cardiol 2021;6:1196-201.
31. Dionne A, Sperotto F, Chamberlain S, Baker AL, Powell AJ, Prakash A, Castellanos DA, Saleeb SF, de Ferranti SD, Newburger JW, Friedman KG. Association of Myocarditis With BNT162b2 Messenger RNA COVID-19 Vaccine in a Case Series of Children. JAMA Cardiol 2021;6:1446-50.
32. Brito D, Meester S, Yanamala N, et al. High Prevalence of Pericardial Involvement in College Student Athletes Recovering From COVID-19. JACC Cardiovasc Imaging 2021;14:541-55.
33. Mitrani RD, Goldberger JJ. Cardiac Arrests During the COVID-19 Pandemic: The Perfect Storm. JACC Clin Electrophysiol 2021;7:12-5.
34. Musikantow DR, Turagam MK, Sartori S, et al. Atrial Fibrillation in Patients Hospitalized With COVID-19: Incidence, Predictors, Outcomes, and Comparison to Influenza. JACC Clin Electrophysiol 2021;7:1120-30.
35. Johansson M, Ståhlberg M, Runold M, et al. Long-Haul Post-COVID-19 Symptoms Presenting as a Variant of Postural Orthostatic Tachycardia Syndrome: The Swedish Experience. JACC Case Rep 2021;3:573-80.
36. O’Connell TF, Bradley CJ, Abbas AE, et al. Hydroxychloroquine/Azithromycin Therapy and QT Prolongation in Hospitalized Patients With COVID-19. JACC Clin Electrophysiol 2021;7:16-25.
37. Leong DP, Eikelboom JW, Yusuf S. The Indirect Consequences of the Response to the COVID-19 Pandemic. J Am Coll Cardiol 2021;77:186-8.
38. Wadhera RK, Shen C, Gondi S, Chen S, Kazi DS, Yeh RW. Cardiovascular Deaths During the COVID-19 Pandemic in the United States. J Am Coll Cardiol 2021;77:159-69.
39. Rappuoli R, De Gregorio E, Del Giudice G, et al. Vaccinology in the post-COVID-19 era. Proc Natl Acad Sci U S A 2021;118:e2020368118.
40. Zheng YY, Ma YT, Zhang JY, Xie X. COVID-19 and the cardiovascular system. Nat Rev Cardiol 2020;17:259-60.
41. Cheng X, Ma C, Han Y. Changes in the work mode of cardiologists during the COVID-19 epidemic in Wuhan. Eur Heart J 2020;41:2729-30.
42. Bhatt AS, Jering KS, Vaduganathan M, et al. Clinical Outcomes in Patients With Heart Failure Hospitalized With COVID-19. JACC Heart Fail 2021;9:65-73.
43. Alvarez-Garcia J, Lee S, Gupta A, et al. Prognostic Impact of Prior Heart Failure in Patients Hospitalized With COVID-19. J Am Coll Cardiol 2020;76:2334-48.
44. Fernández-Ruiz I. RAAS inhibitors do not increase the risk of COVID-19. Nat Rev Cardiol 2020;17:383.
45. Lim GB. Myocardial injury in patients with COVID-19. Nat Rev Cardiol 2020;17:454.
46. Wu L, O’Kane AM, Peng H, Bi Y, Motriuk-Smith D, Ren J. SARS-CoV-2 and cardiovascular complications: From molecular mechanisms to pharmaceutical management. Biochem Pharmacol 2020;178:114114.
47. Sharma T,  Padala PR, Mehta JL. Loneliness and social isolation: determinants of cardiovascular outcomes: Implications in COVID-19 era. Curr Cardiol Rev 2021; 17:e051121190873.
48. Van Belle E, Manigold T, Piérache A, et al. Myocardial Infarction incidence during national lockdown in two French provinces unevenly affected by COVID-19 outbreak: An observational study. Lancet Reg Health Eur 2021;2:100030.
49. Sassone B, Virzì S, Bertini M, et al. Impact of the COVID-19 lockdown on the arrhythmic burden of patients with implantable cardioverter-defibrillators. Pacing Clin Electrophysiol 2021;44:1033-8.
50. Chan DZ, Stewart RA, Kerr AJ, et al. The impact of a national COVID-19 lockdown on acute coronary syndrome hospitalisations in New Zealand (ANZACS-QI55). Lancet Reg Health West Pac 2020;5:100056.
51. Mesnier J, Cottin Y, Coste P, et al. Hospital admissions for acute myocardial infarction before and after lockdown according to regional prevalence of COVID-19 and patient profile in France: a registry study. Lancet Public Health 2020;5:e536-42.
52. Bonnet G, Panagides V, Becker M, et al. MODIF registry investigators. ST-segment elevation myocardial infarction: Management and association with prognosis during the COVID-19 pandemic in France. Arch Cardiovasc Dis 2021;114:340-51.
53. Zachariah G, Ramakrishnan S, Das MK, et al; CSI-AMI Study group. Changing pattern of admissions for acute myocardial infarction in India during the COVID-19 pandemic. Indian Heart J 2021;73:413-23.
54. Holt A, Gislason GH, Schou M, et al. New-onset atrial fibrillation: incidence, characteristics, and related events following a national COVID-19 lockdown of 5.6 million people. Eur Heart J 2020;41:3072-9.
55. Severino P, D’Amato A, Saglietto A, et al. Reduction in heart failure hospitalization rate during coronavirus disease 19 pandemic outbreak. ESC Heart Fail 2020;7:4182-8.
56. Butt JH, Østergaard L, Gerds TA, et al. The Association between Cardiovascular Disease Admission Rates and The Coronavirus Disease 2019 Lockdown and Reopening of a Nation: a Danish Nationwide Cohort Study. Eur Heart J Qual Care Clin Outcomes 2021:qcab021.
57. Rangashamaiah S, Hayagreev V, Krishnan S, Prabhavathi B, Manjunath CN. The impact of COVID19 nationwide lock-down on STEMI hospitalization and outcomes in South India. Indian Heart J 2021;73:379-81.
58. Bromage DI, Cannatà A, Rind IA, et al. The impact of COVID-19 on heart failure hospitalization and management: report from a Heart Failure Unit in London during the peak of the pandemic. Eur J Heart Fail 2020;22:978-84.
59. Jayagopal PB, Abdullakutty J, Sridhar L, et al. Acute decompensated heart failure (ADHF) during COVID-19 pandemic-insights from South India. Indian Heart J 2021;73:464-9.
60. Dover AR, Ritchie SA, McKnight JA, et al. Assessment of the effect of the COVID-19 lockdown on glycaemic control in people with type 1 diabetes using flash glucose monitoring. Diabet Med 2021;38:e14374.
61. Szarfer JL, Puente L, Bono L, et al. Impact of a prolonged COVID-19 lockdown on patterns of admission, mortality and performance indicators in a cardiovascular intensive care unit. Int J Qual Health Care 2021;33:mzab029.
62. Campanile A, Verdecchia P, Ravera A, et al. Intensive cardiac care unit admission trends during the COVID-19 outbreak in Italy: a multi-center study. Intern Emerg Med 2021:1-10.
63. Kostev K, Kumar S, Konrad M, Bohlken J. Prescription rates of cardiovascular and diabetes therapies prior to and during the COVID-19 lockdown in Germany. Int J Clin Pharmacol Ther 2020;58:475-81.
64. Luedde M, Loosen S, Konrad M, Tanislav C, Roderburg C, Kostev K. Increased pharmacy purchases of cardiovascular drugs from wholesalers prior to the first and second COVID-19 lockdowns. Int J Clin Pharmacol Ther 2021;59:572-7.
65. Kwok CS, Gale CP, Curzen N, et al. Impact of the COVID-19 Pandemic on Percutaneous Coronary Intervention in England: Insights From the British Cardiovascular Intervention Society PCI Database Cohort. Circ Cardiovasc Interv 2020;13:e009654.
66. Kwok CS, Gale CP, Kinnaird T, et al. Impact of COVID-19 on percutaneous coronary intervention for ST-elevation myocardial infarction. Heart 2020;106:1805-11.
67. Kobo O, Efraim R, Saada M, et al. The impact of lockdown enforcement during the SARSCoV-2 pandemic on the timing of presentation and early outcomes of patients with ST-elevation myocardial infarction. PLoS One 2020;15:e0241149.
68. Nader J, Anselmi A, Tomasi J, et al. Adult cardiac surgery during COVID-19 lockdown: Impact on activity and outcomes in a high-volume centre. Arch Cardiovasc Dis 2021;114:364-70.
69. Khalil KH, Sá MPBO, Vervoort D, et al. Impact of the COVID-19 pandemic on coronary artery bypass graft surgery in Brazil: A nationwide perspective. J Card Surg 2021;36:3289-93.
70. Roman M, Harky A, Brazier A, et al. Turn down of acute aortic syndrome cases during COVID-19: Results from UK multicentre studies. J Card Surg 2021;36:199-202.
71. Chalasani M, Nasir K, Gupta MD, Kalra A. The Covid-19 pandemic and India’s cardiovascular disease burden: Finding the right balance. Indian J Med Ethics 2020;-(-):1-3.
72. Sacre JW, Holmes-Truscott E, Salim A, et al. Impact of the COVID-19 pandemic and lockdown restrictions on psychosocial and behavioural outcomes among Australian adults with type 2 diabetes: Findings from the PREDICT cohort study. Diabet Med 2021;38:e14611.
73. Li JW, Guo YT, Di Tanna GL, Neal B, Chen YD, Schutte AE. Vital Signs During the COVID-19 Outbreak: A Retrospective Analysis of 19,960 Participants in Wuhan and Four Nearby Capital Cities in China. Glob Heart 2021;16:47.
74. Aktaa S, Yadegarfar ME, Wu J, et al. Quality of acute myocardial infarction care in England and Wales during the COVID-19 pandemic: linked nationwide cohort study. BMJ Qual Saf 2021;bmjqs-2021-013040.
75. Liu J, Zhang L, Yan Y, et al. Excess mortality in Wuhan city and other parts of China during the three months of the covid-19 outbreak: findings from nationwide mortality registries. BMJ 2021;372:n415.
76. Topriceanu CC, Wong A, Moon JC, et al. Impact of lockdown on key workers: findings from the COVID-19 survey in four UK national longitudinal studies. J Epidemiol Community Health 2021;75:955-62.
77. Okely JA, Corley J, Welstead M, et al. Change in Physical Activity, Sleep Quality, and Psychosocial Variables during COVID-19 Lockdown: Evidence from the Lothian Birth Cohort 1936. Int J Environ Res Public Health 2020;18:210.
78. Cammalleri V, Muscoli S, Benedetto D, et al. Who Has Seen Patients With ST-Segment-Elevation Myocardial Infarction? First Results From Italian Real-World Coronavirus Disease 2019. J Am Heart Assoc 2020;9:e017126.
79. Secco GG, Zocchi C, Parisi R, et al. Decrease and Delay in Hospitalization for Acute Coronary Syndromes During the 2020 SARS-CoV-2 Pandemic. Can J Cardiol 2020;36:1152-5.
80. Rieder M, Gauchel N, Kaier K, et al. Pre-medication with oral anticoagulants is associated with better outcomes in a large multinational COVID-19 cohort with cardiovascular comorbidities. Clin Res Cardiol 2021:1-11.
81. Du X, Shi L, Cao W, Zuo B, Zhou A. Add-on effect of Chinese herbal medicine in the treatment of mild to moderate COVID-19: A systematic review and meta-analysis. PLoS One 2021;16:e0256429.
82. Kite TA, Ludman PF, Gale CP, et al; International COVID-ACS Registry Investigators. International Prospective Registry of Acute Coronary Syndromes in Patients With COVID-19. J Am Coll Cardiol. 2021;77(20):2466-76.
83. Garcia S, Dehghani P, Grines C, et al; Society for Cardiac Angiography and Interventions, the Canadian Association of Interventional Cardiology, and the American College of Cardiology Interventional Council. Initial Findings From the North American COVID-19 Myocardial Infarction Registry. J Am Coll Cardiol 2021;77:1994-2003.
84. Guan WJ, Ni ZY, Hu Y, et al. China Medical Treatment Expert Group for Covid-19. China Medical Treatment Expert Group for Covid-19. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020;382:1708-20.
85. Lu YL, Zhu L, Hou GH, et al. Expert consensus on nursing management for patients undergoing primary percutaneous coronary intervention during the COVID-19 pandemic. Cardiol Plus 2020;5:81-8.
86. Hu CS. Analysis of COVID-19 Cases and Public Measures in China. SN Compr Clin Med 2020;2:1306-12.
87. Shi S, Qin M, Shen B, et al. Association of Cardiac Injury With Mortality in Hospitalized Patients With COVID-19 in Wuhan, China. JAMA Cardiol 2020;5:802-10.
88. Shi S, Qin M, Cai Y, et al. Characteristics and Clinical Significance of Myocardial Injury in Patients With Severe Coronavirus Disease 2019. Eur Heart J 2020;41:2070-9.
89. Chen Q, Xu L, Dai Y, et al. Cardiovascular manifestations in severe and critical patients with COVID-19. Clin Cardiol 2020;43:796-802.
90. Xiang D, Xiang X, Zhang W, et al. Management and Outcomes of Patients With STEMI During the COVID-19 Pandemic in China. J Am Coll Cardiol 2020:76:1318-24.
91. Han Y, Zeng H, Jiang H, et al. CSC Expert Consensus on Principles of Clinical Management of Patients with Severe Emergent Cardiovascular Diseases during the COVID-19 Epidemic. Circulation 2020;141:e810-6.
92. Li H, Gu X, Li H, et al. Risk factors of viral RNAaemia and its association with clinical prognosis among patients with severe COVID-19. Chest 2021;159:1382-6.
93. Stephenson KE, Le Gars M, Sadoff J, et al. Immunogenicity of the Ad26.COV2.S Vaccine for COVID-19. JAMA 2021;325:1535-44.
94. Turner JS, O’Halloran JA, Kalaidina E, et al. SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses. Nature 2021;596:109-13.
95. Bartsch YC, Tong X, Kang J, et al. Omicron variant Spike-specific antibody binding and Fc activity is preserved in recipients of mRNA or inactivated COVID-19 vaccines. Sci Transl Med. 2022:eabn9243.
96. Cheng SMS, Mok CKP, Leung YWY, et al. Neutralizing antibodies against the SARS-CoV-2 Omicron variant BA.1 following homologous and heterologous CoronaVac or BNT162b2 vaccination. Nat Med 2022;28:486-9.
97. Chen GL, Li XF, Dai XH, et al. Safety and immunogenicity of the SARS-CoV-2 ARCoV mRNA vaccine in Chinese adults: a randomised, double-blind, placebo-controlled, phase 1 trial. Lancet Microbe 2022;3:e193-202.
98. Rauseo AM, O’Halloran JA. What Are the Clinical Implications of the SARS-CoV-2 Variants: 5 Things Every Cardiologist Should Know. JACC Basic Transl Sci 2021;6:305-8.
99. Cui X, Wang P, Wei Z. Emergency use of COVID-19 vaccines recommended by the World Health Organization (WHO) as of June 2021. Drug Discov Ther 2021;15:222-4.
100. Kotoulas AS, Karamanavis D, Lambrou GΙ, Karanikas P. A pilot study of the depression, anxiety and stress in Greek military personnel during the first year of the COVID-19 pandemic. BMJ Mil Health 2021;bmjmilitary-2021-001874.
101. Hu CS, Tkebuchava T, Wu QH, Hu DY. C-type hypertension:an ignored new killer? Cardiology Plus 2017;2:1-4.
102. Hu C, Tkebuchava T. Soccer Related Emotion and Stress-induced Cardiovascular Events. Cardiology Plus 2018;3:66-70.
103. García-Fiñana M, Hughes DM, Cheyne CP, et al. Performance of the Innova SARS-CoV-2 antigen rapid lateral flow test in the Liverpool asymptomatic testing pilot: population based cohort study. BMJ 2021;374:n1637.
104. Hu C, Tkebuchava T. Visual and measured clinical phenotypes: Potential targets for cardiovascular prevention. Cardiology Plus 2019;4:43-6.
105. Gu RP, Li T, Zheng LP. Psychological safeguards for Chinese People’s Liberation Army fighting COVID-19. BMJ Mil Health 2020;166:443.
106. Parsons IT, Gifford RM, Stacey MJ, Lamb LE, O’Shea MK, Woods DR. Does vitamin D supplementation prevent SARS-CoV-2 infection in military personnel? Review of the evidence. BMJ Mil Health 2021;167:280-6.
107. Greenberg N, Cooke J, Sullivan E, Tracy DK. Mental health plan for workers of the London Nightingale Hospital: following the evidence to support staff. BMJ Mil Health 2021;167:107-9.
108. Lamontagne F, Agoritsas T, Siemieniuk R, et al. A living WHO guideline on drugs to prevent covid-19. BMJ 2021;372:n526.
109. Arena R, Bond S, Calvo IR, et al. HL-PIVOT Network. Shelter from the cytokine storm: Healthy living is a vital preventative strategy in the COVID-19 era. Prog Cardiovasc Dis 2021;S0033-0620(21)00066-9.
110. Xie Y, Xu E, Bowe B, Al-Aly Z. Long-term cardiovascular outcomes of COVID-19.  Nat Med 2022;28:583-90.
111. Gupta S, Mitra A. Challenge of post-COVID era: management of cardiovascular complications in asymptomatic carriers of SARS-CoV-2. Heart Fail Rev 2022;27:239-49.
112. Sigfrid L, Cevik M, Jesudason E, et al. What is the recovery rate and risk of long-term consequences following a diagnosis of COVID-19? A harmonised, global longitudinal observational study protocol. BMJ Open 2021;11:e043887.
113. Nakayama A, Takayama N, Kobayashi M, et al. Remote cardiac rehabilitation is a good alternative of outpatient cardiac rehabilitation in the COVID-19 era. Environ Health Prev Med 2020;25:48.
114. Żak MM, Stock A, Stadlbauer D, et al. Development and characterization of a quantitative ELISA to detect anti-SARS-CoV-2 spike antibodies. Heliyon 2021;7:e08444.
115. Ciampi Q, Antonini-Canterin F, Barbieri A, et al. SIECoVId Study Group On Behalf Of The Italian Society Of Echocardiography And Cardiovascular Imaging Siecvi. Reshaping of Italian Echocardiographic Laboratories Activities during the Second Wave of COVID-19 Pandemic and Expectations for the Post-Pandemic Era. J Clin Med 2021;10:3466.
116. Kaushik A, Patel S, Dubey K. Digital cardiovascular care in COVID-19 pandemic: A potential alternative? J Card Surg 2020;35:3545-50.
117. Suri JS, Agarwal S, Gupta SK, et al. A narrative review on characterization of acute respiratory distress syndrome in COVID-19-infected lungs using artificial intelligence. Comput Biol Med 2021;130:104210.
118. Hikisz P, Bernasinska-Slomczewska J. Beneficial Properties of Bromelain. Nutrients 2021;13:4313.
119. Rao G, Singh A, Gandhotra P, et al. Paradigm Shifts in Cardiac Care: Lessons Learned From COVID-19 at a Large New York Health System. Curr Probl Cardiol 2021;46:100675.
120. Hu C. Combat COVID-19 with “ISISI” Strategies for Human Cardiocerebrovascular Health. Manuscript in Submission & Under Review. 2022.